4:06 PM ET
8-K
M&A Deal
Insight Molecular Diagnostics M&A Deal with Chronix Biomedical, Inc.
Insight Molecular Diagnostics (iMDx) entered into Amendment No. 2 to its merger agreement with Chronix, modifying the earnout structure related to the CNI Monitor technology. The amendment establishes that equity holders will receive a 10% royalty on sales until a potential sale of the technology occurs, at which point they will receive a final payment of 10% of the gross sale proceeds.
- Counterparty
- Chronix Biomedical, Inc.